Proactive Investors - Run By Investors For Investors

Collagen Solutions signs new ChondroMimetic licence and distribution deal in Indonesia

Rajawali Medika will work with Collagen to obtain regulatory approval and launch ChondroMimetic in Indonesia and possibly several other South East Asian countries
knee operation
ChondroMimetic is a tissue scaffold which helps to regenerate damaged knee cartilage

Regenerative medicines group Collagen Solutions PLC (LON:COS) has signed a new licence and distribution agreement for its knee cartilage scaffold ChondroMimetic with an Indonesian partner.

Rajawali Medika will work with Collagen to obtain regulatory approval and launch ChondroMimetic in Indonesia with the potential of several other South East Asian countries.

READ: Collagen Solutions signs manufacturing agreement for Excellagen wound-healing product

Collagen said the Jakarta-based company was “highly experienced” in selling and marketing medical devices in the Asia Pacific region and has a “strong network” of orthopaedic surgeons and sales distribution channels.

“We are pleased to enter the partnership agreement with Rajawali Medika for ChondroMimetic in South East Asia,” said chief executive Jamal Rushdy.

“We will benefit enormously from both their in-depth expertise in the area of sports medicine procedures as well as their regional presence.

“This agreement adds to other distributor agreements that we have been putting in place in Asia and Europe in order to initiate our launch of ChondroMimetic soon after we obtain regulatory approval.”

ChondroMimetic is a minimally-invasive surgically placed scaffold which helps to repair knee cartilage.

Last February, results from an eight-year clinical extension study showed that ChondroMimetic was able to regenerate cartilage to a structural quality almost identical to native cartilage.

CE Mark timing ‘uncertain’

Work on a CE Mark application, which would signify that the product has passed safety, health and environmental protection requirements, began almost straight away.

Collagen had hoped to hear whether or not it had been successful by the end of March, although with the process being out of its control, it admits that the timing of any award is “uncertain”. Currently, ChondroMimetic is not approved for sale in any markets.

“We are currently awaiting feedback regarding our CE Mark submission and we will provide an update once new information becomes available and certainly no later than our proposed April trading update,” added CEO Rushdy.

Collagen Solutions shares rose 3.8% to 4.2p in late-afternoon trading on Thursday.

-- Adds share price --

View full COS profile View Profile

Collagen Solutions PLC Timeline

Related Articles

lung x-ray
May 07 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
test tubes
April 16 2019
Summit Therapeutics' potential breakthrough targets C.difficile
man with erectile dysfunction
April 26 2019
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use